dexamethasone injection / Generic mfg. - LARVOL DELTA

Experimental Evidence of Dexamethasone in Reversing Endothelial Dysfunction in COVID-19: Therapeutic Insights from Intranasal Administration. (PubMed, Clin Ther) - "The IN-DXM regimen produced greater improvement in respiratory and inflammatory parameters than IV-DXM, supporting its potential as a practical and effective alternative for managing severe COVID-19-associated endothelial dysfunction."

Journal • Infectious Disease • Novel Coronavirus Disease • CRP • IL6

Ruxolitinib With De-Intensified HLH-94 for the Treatment of Hemophagocytic Lymphohistiocytosis (HLH) (clinicaltrials.gov) - P2 | N=36 | Recruiting | Sponsor: Jerry Lee, MD, MSc, MPhil | Suspended ➔ Recruiting | Trial completion date: Nov 2027 ➔ Nov 2029

Enrollment open • Trial completion date • Hemophagocytic lymphohistiocytosis • Immunology • Rare Diseases

This is a title in sentence case:early intrathecal dexamethasone and methotrexate as an effective approach for immune effector cell-associated neurotoxicity syndrome after CAR-T cell therapies (ASH 2025) - "Median duration of intravenous dexamethasone before first IDM was 6(1-7) (days). Our data shows that early administration of IDM is feasible and highly effective in management of severe or steroid-refractory ICANS and improving short-term prognosis, which may create opportunities for subsequent treatments in these patients. Larger sample and multicenter clinical trials are warranted to further validate these findings."

CAR T-Cell Therapy • Clinical • Acute Myelogenous Leukemia • B Cell Lymphoma • Hematological Malignancies • Leukemia • Lymphoma • Non-Hodgkin’s Lymphoma • CD123 • CD22 • CD7 • IL3RA

Safety and efficacy of glofitamab in combination with lenalidomide in relapsed or refractory central nervous system lymphoma: Real-world data (ASH 2025) - "Pretreatment with obinutuzumab (1000 mg) was administered intravenously 7 days before the first dose of glofitamab. Glofitamab was then administered intravenously by step-up dosing during cycle 1 (day 8: 2.5 mg; day 15: 10 mg), followed by fixed-dose glofitamab 30 mg on day 1 of cycles 2~12 To mitigate the risk of cytokine release syndrome (CRS), patients received premedication (dexamethasone 20mg intravenously, acetaminophen 1000mg orally, isopropanazine 25mg intramuscularly) 1 hour before glofitamab therapy... The cohort comprised one male and three females, with a mean age of 58 years (range: 51~69). Median time to relapse after last treatment was 5 months (range: 3~8). Relapse symptoms included neurological symptoms (such as headache, lethargy, limb weakness, gait disturbance, slurred speech, visual deficits, etc.) and systemic symptoms (such as nausea, anorexia, fatigue, etc.) After two cycles of treatment, all patients achieved rapid remission (two complete..."

Clinical • Combination therapy • Real-world • Real-world evidence • Anorexia • B Cell Lymphoma • Brain Cancer • CNS Lymphoma • Diffuse Large B Cell Lymphoma • Hematological Malignancies • Lymphoma • Non-Hodgkin’s Lymphoma • Solid Tumor • CD20

Immune thrombotic thrombocytopenic purpura in Armenia: A case series highlighting the role of early empiric therapy and multidisciplinary management (ASH 2025) - "Treatment with plasma exchange (PEX) (8 sessions), IV dexamethasone, and rituximab (4 doses on 1, 4, 8, 9 days) led to full hematologic recovery. However, he developed aggressive behavioral changes that persisted beyond hematologic recovery. Following the fourth infusion of Rituximab, hematologic parameters improved rapidly, and the neurologic symptoms fully resolved."

Clinical • CNS Disorders • Hematological Disorders • Thrombocytopenia • Thrombocytopenic Purpura • HP

Pure IgA-mediated hemolytic anemia. a rare and challenging diagnosis of "Coombs Negative" hemolytic anemia, with successful management (ASH 2025) - "The patient received a course of dexamethasone IV 40 mg X 4 days and IVIG 1 gram/Kg, daily X2...She was transitioned to prednisone at discharge, and the dose was gradually tapered to 20 mg daily, without relapse 10 months later... Educational Points: "When you have eliminated all which is impossible, then whatever remains, however improbable, must be the truth," per Sherlock Holmes, in The Sign of Four, Sir Arthur Conan Doyle. This case illustrates a true diagnostic dilemma, as the standard approach to the diagnosis of severe, life-threatening hemolytic anemia was unrevealing. It was only when we considered an improbable etiology, i.e. pure IgA-mediated immune hemolytic anemia, despite repeated negative DAT, did we identify the diagnosis."

Anemia • Hematological Disorders • HP

Feasibility and safety of accelerated glofitamab step-up in rapidly progressive relapsed/refractory diffuse large B-cell lymphoma: A real-world single center experience (ASH 2025) - P2 | "Dosing was as follows: Cycle (C) 1—obinutuzumab1000 mg (Day [D] 1), glofitamab 2.5 mg (D4), 10 mg (D6), 30 mg (D11)...Before Oct 2024, patientsreceived 20 mg IV dexamethasone (dex) as premedication (premed group); thereafter prophylactic dex10 mg PO (D5, 7–9, 12–14) was added (prophy group)... In a real-world study of glofitamab aSUD in high-risk R/R DLBCL, most pts completed Cycle1, and some pts could be successfully bridged to CAR T or alloHCT. However, CRS/ICANS incidence washigher, and efficacy outcomes were lower than reported in clinical trials, consistent with their high-riskprofile. Dex prophylaxis did not significantly reduce CRS incidence or severity over a small sample size oftreated pts."

Clinical • Real-world • Real-world evidence • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Gastroenterology • Genito-urinary Cancer • Hematological Malignancies • High-grade B-cell lymphoma • Infectious Disease • Lymphoma • Non-Hodgkin’s Lymphoma • Renal Cell Carcinoma • Solid Tumor • BCL2 • BCL6

Favorable preliminary safety and efficacy of mosunetuzumab plus ICE or DHAX salvage chemotherapy in relapsed/refractory large B-cell lymphoma (ASH 2025) - P1 | "With universal prior rituximab exposure in pts withR/R LBCL, salvage strategies may be improved by incorporating novel agents instead of rituximabretreatment...All pts receive at least 2 cyclesof concurrent Mosun + platinum-based chemotherapy, with chemotherapy per treating physician (Arm A:dexamethasone, cytarabine, oxaliplatin [DHAX]; Arm B: ifosfamide, carboplatin, etoposide [ICE])...Pts receive 20mg IV dexamethasone prior to each C1-C2Mosun dose, with optional steroid premeds thereafter...Nine pts experienced CRS (all gr1; no tocilizumab required)... Mosun + DHAX/ICE demonstrated a manageable safety profile with low-grade CRS.Preliminary efficacy results reveal promising anti-lymphoma activity in a high-risk population, with highCR rate and no progressions after CR with relatively short follow-up. This regimen is encouraging forfurther study. Long-term efficacy data are awaited to better assess remission durability."

Clinical • B Cell Lymphoma • Cardiovascular • CNS Disorders • CNS Lymphoma • Gastroenterology • Gastrointestinal Disorder • Hematological Disorders • Hematological Malignancies • Hepatology • Infectious Disease • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Psychiatry • Septic Shock • Thrombocytopenia • Thrombosis • CD20

Long-term outcomes of a chemotherapy-free regimen of concomitant blinatumomab and inotuzumab ozogamicin in older patients with Philadelphia negative B-cell acute lymphoblastic leukemia (ASH 2025) - "Pts received the following treatment during cycle 1: dexamethasone 20 mgintravenously (IV) days 1-4, vincristine 1 mg IV day 4, fractionated InO 0.6 IV mg/m2 day 1 and 0.3 IVmg/m2 day 8 followed by blina IV days 15-28 (9 ug/day x 2 days followed by 28 ug/daily) followed by 2-week rest...Pts with CD20 positive ALL could receive rituximab 375 mg/m2 IV on days 2 and 9during cycles 1-4. Pts received 12 doses of intrathecal chemotherapy and ursodiol...There were no episodes of veno-occlusive disease.ConclusionA largely chemotherapy-free regimen of blina in combination with InO for older or unfit pts was toleratedand resulted in high rates of MRD-negative remission with 2-year survival rates of 50%. Most deaths areattributable to non-relapse mortality, suggesting that continued optimization of treatment regimens areneeded for older pts with B-cell ALL."

Clinical • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Hematological Disorders • Hematological Malignancies • Hepatology • Infectious Disease • Leukemia • Leukopenia • Myocardial Infarction • Neutropenia • Respiratory Diseases • Thrombocytopenia • CD20 • CRLF2 • KMT2A

Daratumumab plus cyclophosphamide, bortezomib and dexamethasone in newly diagnosed patients with light-chain amyloidosis: Interim analysis from an Italian, multicenter, retro-prospective real-world experience (ASH 2025) - "Few real-world studies assessed Daratumumab alone or withbortezomib or lenalidomide; however, data on its combination with CyBorD outside clinical trials remainlimited...All patients received "CyBor_Dq" regimenupfront (subcutaneous bortezomib 1.3 mg/m², cyclophosphamide 300 mg/m² orally or IV, anddexamethasone 40 mg orally or IV weekly for six 28-day cycles, plus subcutaneous Daratumumab 1800mg—weekly in cycles 1-2, every two weeks in cycles 3-6, then monthly up to 24 cycles or progression—ina real-world setting)...The challenge is to find earlypredictors of treatment response and improve patient outcomes. Additional follow-up data are needed toconfirm these initial results and guide the development of future personalized treatment approaches."

Clinical • Real-world • Real-world evidence • Amyloidosis • Cardiovascular • Constipation • Gastroenterology • Gastrointestinal Disorder • Pulmonary Disease • Renal Disease • Thrombocytopenia

Double or triple therapy in newly diagnosed immune thrombocytopenia: Improving outcomes from the west-central Mexican experience. (ASH 2025) - "Treatment consisted of oral or IV dexamethasone 40mg daily for 4 days every 21 days for two cycles; eltrombopag 50 mg daily for 28 days, suspended ifplatelet counts rise above 400x109/L; and azathioprine 2 mg/kg/day for 42 days in DEA arm. With this latter group the DOR was better at 180 and maintained at 360 days.The cornerstone in the treatment has been with steroids, but differences in type of steroid and number ifcycles remain unanswered, even more with combinations, and the Introduction of new agents (BloodReviews 2025,101300). Multicentric clinical trials are needed to evaluate the combined therapy that willbring long lasting complete remissions or even cure in the first line of therapy."

Immune Thrombocytopenic Purpura • Immunology • Infectious Disease • Thrombocytopenia • Thrombocytopenic Purpura

Pola-R-edch shows high response rates in high-risk aggressive B-cell lymphomas or PMBCL: A phase 2 study (ASH 2025) - "However, the safety and efficacy ofincorporating Pola into modified R-EDCH (with vincristine omission and dexamethasone substitution)remains unknown...All participants received six 21-daycycles of Pola-R-EDCH, consisting of polatuzumab vedotin (1.8 mg/kg IV, day 1), rituximab (375 mg/m² IV,day 0), etoposide (50 mg/m²/day continuous IV infusion, days 1-4), liposomal doxorubicin (30-40 mg/m² IV,day 1), cyclophosphamide (750 mg/m² IV, day 5), and dexamethasone (30 mg IV, days 1-5)...Febrile neutropenia was reported in 43.8% of cases.Peripheral neuropathy occurred in 50% of patients, all of which were grade 1 or 2.ConclusionsThe Pola-R-EDCH regimen demonstrated high response rates in patients with PMBCL or high-risk LBCL.The addition of polatuzumab vedotin did not result in unexpected toxicities. Patients with TP53abnormalities, with or without CDKN2A depletion, showed an increased risk of disease progression."

IO biomarker • P2 data • B Cell Lymphoma • Diffuse Large B Cell Lymphoma • Febrile Neutropenia • Hematological Disorders • Hematological Malignancies • High-grade B-cell lymphoma • Lymphoma • Neutropenia • Non-Hodgkin’s Lymphoma • Primary Mediastinal Large B-Cell Lymphoma • Thrombocytopenia • BCL2 • BCL6 • CD79B • CDKN2A • TP53

A standardized rapid dose escalation of epcoritamab for patients with lymphoid malignancies (ASH 2025) - "Supportive care with 500 ml intravenous fluids,dexamethasone (dex) 16 mg, acetaminophen 650 mg, and diphenhydramine 50 mg was administered 30-120 minutes prior to each epco injection, including through the completion of cycle (C) 1...Three pts received epco incombination with gemcitabine and oxalipatin...CRS was treated with tocilizumab (toci) alone in all 3 pts... We report a standardized process with enhanced supportive care in C1 for a rapid doseescalation of epco, enabling pts to achieve the 1st full therapeutic dose on D 7. This approach hasdemonstrated feasibility and safety. All CRS events were low grade and resolved quickly."

Clinical • B Cell Lymphoma • Chronic Lymphocytic Leukemia • Diffuse Large B Cell Lymphoma • Follicular Lymphoma • Hematological Malignancies • High-grade B-cell lymphoma • Large B Cell Lymphoma • Lymphoma • Non-Hodgkin’s Lymphoma • Oncology

Efficacy and safety of RCD pulse regimen for acquired Hemophilia A (ASH 2025) - "TheRCD pulse regimen is a combined immunosuppressive therapy (IST) consisting of: 500mgcyclophosphamide intravenously on days 1, 8, 15, and 22; 40mg dexamethasone, intravenously or orally,on days 1, 8, 15, and 22; and 100mg rituximab intravenously on days 1, 8, 15, and 22...All patients received infection prophylaxis with sulfamethoxazole and trimethoprim (480 mgonce daily) and acyclovir (400 mg once daily)...Two patientswith inhibitors > 100 BU and 2 patients with inhibitors < 20 BU did not achieve CR after prednisolonealone or combination therapy with the addition of cyclophosphamide prior to RCD.To date, 7 of the 8 (87.5%) patients have achieved CR after 1 or 2 courses of RCD (3 newly diagnosedpatients after 1 courses of RCD, 1 newly diagnosed patient and 3 relapsed patients after 2 courses ofRCD). One patient who relapsed after 313 weeks of treatment with prednisone and other drugs cannotbe treated strictly in accordance with the protocol of this study, and has..."

Clinical • Breast Cancer • Cataract • CNS Disorders • Coronary Artery Disease • Depression • Diabetes • Gastroenterology • Gastrointestinal Disorder • Glomerulonephritis • Heart Failure • Hemophilia • Hemophilia A • Hypertension • Immunology • Infectious Disease • Interstitial Lung Disease • Metabolic Disorders • Nephrology • Ophthalmology • Pneumonia • Psychiatry • Rare Diseases • Renal Disease • Respiratory Diseases • Rheumatology • Solid Tumor

Anterior Quadratus Lumborum Block: A Regional Anaesthetic Technique for the Management of Acute Back Pain in the Emergency Department. (PubMed, Cureus) - "Given ongoing severe pain (NRS = 8/10), ultrasound-guided bilateral AQLB was performed using 30 mL of 0.18% ropivacaine on each side with a 21G SonoPlex®II needle (Pajunk®, Geisingen, Germany), accompanied by intravenous dexamethasone (6 mg). This case suggests that AQLB is a feasible and effective opioid-sparing rescue technique for the management of acute back pain in the ED secondary to QL syndrome. It adds to emerging evidence supporting its role as a safe, effective, and resource-efficient intervention, meriting further prospective evaluation."

Journal • Anesthesia • Back Pain • Chronic Kidney Disease • Musculoskeletal Pain • Nephrology • Pain • Renal Calculi • Renal Disease

Needle and Nodule: A Case of Intra-Lesional Success in Oral Mucocele Treatment. (PubMed, Clin Case Rep) - "A 26-year-old male with a lower lip mucocele was successfully treated using weekly intralesional injection of Dexamethasone (2 mL) for 3 weeks. This non-surgical approach leads to the complete resolution of the lesion within a four-week duration with no recurrence during follow-up. Such a treatment modality highlights the effectiveness as a minimally invasive alternative for the management of mucocele of the oral cavity."

Journal

Dexamethasone for prevention of hypoglycemic seizures in the imminently dying - the counterintuitive answer? - A Young Oncologist case report (ESMO Asia 2025) - "She was started on dexamethasone intravenously, which helped prevent any further recurrent episodes...It may be possible that, considering the paucity of available options, seemingly innocuous interventions might assume added practical significance when visualized through the prism of necessity. Application of Internal medicine knowledge might prove to be crucial in developing and nurturing a rational and practical approach to decision-making in specialist palliative medicine."

Case report • Clinical • Hepatocellular Cancer • Oncology • Solid Tumor

Gestational Glucocorticoids' Exposure Impairs Vascular Contractility in Male Offspring Mice With Transgenerational Effects. (PubMed, Arterioscler Thromb Vasc Biol) - "To model gestational glucocorticoid exposure, pregnant mice received intraperitoneal injections of dexamethasone (a synthetic glucocorticoid) on gestational days 12, 14, 16, and 18...This study demonstrates that gestational glucocorticoids' exposure triggers transgenerational inheritance of vascular dysfunction in male offspring via DNA methylation reprogramming, providing direct evidence for the epigenetic transmission of acquired traits. These findings advance our understanding of intergenerational disease mechanisms and offer novel insights for clinical strategies aimed at mitigating the adverse effects of gestational glucocorticoid therapy."

Journal • Preclinical

Chemotherapy Free Regimen of Inotuzumab Ozogamicin and Blinatumomab in Frontline Therapy of Older Patients with Philadelphia Negative B-Cell Acute Lymphoblastic Leukemia (ASH 2024) - "Treatment consisted of Dexamethasone intravenous (IV) 20 mg (Day) D1-D4 and vincristine 1 mg IV on D4 with fractionated InO 0.6 mg/m2 on D1 and 0.3 mg/m2 on D8, in Cycle (C) 1...CNS prophylaxis with alternating IT methotrexate and cytarabine was administered for 12 doses...All pts received ursodeoxycholic acid prophylaxis...11 pts (79%) received rituximab...Conclusion : A chemotherapy minimized combination of InO and Blina leads to promising response and survival outcomes in older pts with newly diagnosed B-ALL and appears tolerable. Longer follow up to assess safety, continued efficacy and incidence of secondary myeloid neoplasms is needed in this population."

Clinical • IO biomarker • Acute Lymphocytic Leukemia • B Acute Lymphoblastic Leukemia • Cardiovascular • CNS Disorders • Hematological Disorders • Hematological Malignancies • Hepatology • Infectious Disease • Leukemia • Movement Disorders • Myocardial Infarction • Neutropenia • Oncology • Pneumonia • Respiratory Diseases • CD20 • CRLF2 • KMT2A • TP53

Dexamethasone Versus Prednisolone in Acute Exacerbation of Childhood Asthma (clinicaltrials.gov) - P=N/A | N=224 | Completed | Sponsor: Muhammad Aamir Latif

New trial • Asthma • Immunology • Pulmonary Disease • Respiratory Diseases

Intravenous Dexamethasone Administered Perioperatively vs 8 Hours Prior to Incision to Control Pain after Total Knee Arthroplasty. A Prospective Randomized Clinical Trial. (PubMed, Arthroplast Today) - "The outcomes included a visual analog scale (VAS) for pain, morphine consumption, frequency of postoperative nausea and vomiting, knee circumference, C-reactive protein levels, and blood glucose levels. Perioperative dexamethasone injection provides comparable clinical outcomes and inflammation level after TKA to those administered 8 hours prior to incision. Thus, both intravenous dexamethasone approach can be an option for current clinical pathways of TKA."

Clinical • Journal • Diabetes • Infectious Disease • Inflammation • Mood Disorders • Orthopedics • Pain • CRP

Amelanotic melanoma of the central nervous system with systemic spread - imaging pitfalls and clues in a rare paediatric case with congenital melanocytic naevi. (PubMed, Childs Nerv Syst) - "She was treated with targeted therapy comprising trametinib and azacitidine, with a plan for immunotherapy (nivolumab and ipilimumab) after weaning off intravenous dexamethasone for cord compression. This case underscores the diagnostic challenge due to imaging similarities with other neoplastic, infectious and inflammatory pathologies. Given the aggressive nature and poor prognosis, a high index of suspicion should be raised for melanoma in patients with CMN and neurocutaneous melanosis who develop progressive neurological symptoms."

Journal • CNS Disorders • Epilepsy • Melanoma • Oncology • Pediatrics • Solid Tumor • Ventriculomegaly

Effect of intravenous dexamethasone on duration of analgesia following popliteal nerve block in pediatric ankle surgery: A randomized, triple-blinded clinical trial. (PubMed, J Clin Anesth) - P4 | "Intravenous dexamethasone effectively prolongs analgesia and reduces opioid requirements after pediatric foot and ankle surgery. While 0.2 mg/kg provides maximal benefit, 0.1 mg/kg may offer an optimal balance between efficacy and metabolic safety."

Journal • Addiction (Opioid and Alcohol) • Anesthesia • Orthopedics • Pain • Pediatrics

CARTITUDE-2: A Study of JNJ-68284528, a Chimeric Antigen Receptor T Cell (CAR-T) Therapy Directed Against B-cell Maturation Antigen (BCMA) in Participants With Multiple Myeloma (clinicaltrials.gov) - P2 | N=210 | Active, not recruiting | Sponsor: Janssen Research & Development, LLC | Recruiting ➔ Active, not recruiting

Enrollment closed • Hematological Malignancies • Multiple Myeloma • Oncology

Delayed Dexamethasone Absorption from Gluteal Abscesses: Persistent Iatrogenic Cushing Syndrome. (PubMed, Clin Med Insights Endocrinol Diabetes) - "We present a case involving prolonged exposure to glucocorticoids from intramuscular dexamethasone injections, with diagnosis confirmed via abscess fluid analysis...Overall, atypical pharmacokinetics are important in cases of unexplained hypercortisolism, especially when local tissue alterations influence drug absorption and clearance. Analyzing collections like abscess fluid can provide vital diagnostic clues in complex suspected cases of iatrogenic Cushing syndrome."

Journal • Back Pain • Cardiovascular • Cushing’s Disease • Endocrine Disorders • Hypertension • Musculoskeletal Pain • Pain